[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Campagne G, Roca M, Martínez A: Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol; 2003 Aug 15;109(2):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect.
  • Imiquimod modulates the immune response, and is a new approach for treatment of papillomavirus-associated lesions, although it has not been approved for the treatment of intraepithelial neoplasia.
  • We present a case of a patient treated with imiquimod on account of high-grade intraepithelial neoplasia in the vulva and other locations.
  • The posterior biopsies confirm the absence of lesions but show drug-induced pemphigus as a side effect.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Genital Neoplasms, Female / therapy. Pemphigus / chemically induced. Vulvar Diseases / chemically induced
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Carcinoma in Situ / virology. Female. Humans. Papillomaviridae / drug effects. Papillomavirus Infections / chemically induced. Treatment Outcome. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy. Uterine Cervical Neoplasms / virology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy. Vaginal Neoplasms / virology. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / therapy. Vulvar Neoplasms / virology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):242-3 [15262368.001]
  • (PMID = 12860347.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


2. Atkins KA, Jeronimo J, Stoler MH, ALTS Group: Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer; 2006 Aug 25;108(4):212-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study.
  • BACKGROUND: The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) accumulated information regarding conventional and liquid-based Papanicolaou (Pap) cytology, 2 kinds of human papillomavirus (HPV) DNA testing, cervicography, and colposcopically directed biopsy.
  • The prevalence of squamous cell carcinoma in these women, the efficacy of tests, and the time to detection were reviewed.
  • All results of colposcopy, HPV testing, cytology, biopsies, and cervigrams were reviewed for all women in the ALTS trial who were diagnosed with squamous cell carcinoma.
  • RESULTS: There were 7 diagnoses of invasive cancer (all squamous cell) during the 2 years of the ALTS trial.
  • Although the enrollment studies isolated many high-grade lesions, none of those results were diagnostic of the underlying carcinoma.
  • CONCLUSIONS: The prevalence of squamous cell carcinoma in the setting of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology interpretation appears to be low (approximately 1 per 1000 women in the ALTS trial).
  • Type-specific testing identified HPV type 16 in 6 of 7 cancers and HPV type 18 in 1 of 7 cancers.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16680733.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / CN-55105; United States / NCI NIH HHS / CN / CN-55152; United States / NCI NIH HHS / CN / CN-55154; United States / NCI NIH HHS / CN / CN-55155; United States / NCI NIH HHS / CN / CN-55156; United States / NCI NIH HHS / CN / CN-55157; United States / NCI NIH HHS / CN / CN-55158; United States / NCI NIH HHS / CN / CN-55159
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


3. Ayas S, Karateke A, Aköz I, Kir G, Yenidede I: Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report. Eur J Gynaecol Oncol; 2007;28(6):501-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report we present a rare case of primary carcinoma of the fallopian tube with synchronous cervical high-grade squamous intraepithelial lesion (HSIL).
  • The histological diagnosis on cervical biopsy and conization material were of cervical intraepithelial neoplasia III (CIN III).
  • Postoperatively the patient received six cycles of adjuvant chemotherapy (carboplatin and paclitaxel) and is still under routine control.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fallopian Tube Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis


Advertisement
4. Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R: Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance.
  • To find the sensitivity, specificity, and positive and negative predictive values of the high-risk group human papillomavirus (HPV) DNA testing as a triage tool to detect high-grade squamous intraepithelial lesions (HSILs, ie, cervical intraepithelial neoplasia [CIN] 2 or worse) in women with a cytologic smear showing atypical squamous cells of undetermined significance (ASC-US).
  • Of the 90 ASC-US cases enrolled, the pathologic results were normal in 30.0%, squamous metaplasia in 16.7%, CIN 1 in 37.8%, CIN 2 in 1.1%, CIN 3 in 11.1%, and microinvasive cervical carcinoma in 3.3%.
  • The prevalence of HSILs and the prevalence of high-risk HPV detection were 15.6% and 38.9%, respectively.
  • High-risk group HPV detection can be used as an additional triage test to detect HSILs in women having ASC-US with high sensitivity and negative predictive value.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Cohort Studies. DNA Probes, HPV. Female. Humans. Immunohistochemistry. Middle Aged. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Risk Assessment. Sensitivity and Specificity. Thailand. Triage


5. Stanley MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res; 2002 Nov;89(2):241-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and new therapeutic approaches to cervical cancer.
  • Recent advances in the detection and therapy of carcinoma of the cervix and its squamous intra-epithelial precursor lesions exploit the knowledge that these lesions are a consequence of infection with high risk (HR) human papillomavirus (HPV).
  • Detection of HR HPV DNA in smears from selected patient groups will improve detection of high grade precursor lesions and immunodetection of the cell cycle dependent kinase inhibitor p16(INK4a) seems to specifically and sensitively identify HGSIL.
  • Immunisation with HPV early proteins has been shown to have both prophylactic and therapeutic efficacy in animal papillomavirus infections and immunotherapies for low grade intra-epithelial lesions are realistic.
  • Immunotherapies for HPV associated high grade pre-cancers and invasive cancers are problematic in view of tumour immune evasion.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae / immunology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines / therapeutic use
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Female. Genes, p16. Humans. Papillomavirus Infections / drug therapy. Prognosis. Tumor Virus Infections / drug therapy


6. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS; 2006 May 12;20(8):1151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
  • OBJECTIVES: To test a therapeutic vaccine consisting of a fusion of the human papillomavirus (HPV) 16 E7 protein and the Mycobacterium bovis heat shock protein 65 (SGN-00101) to treat high-grade anal intraepithelial neoplasia (HG-AIN) in HIV-positive individuals.
  • DESIGN: A phase I/II trial with three cohorts of five participants each, sequentially assigned to receive 100, 500 or 1000 microg SGN-00101, injected three times subcutaneously in alternating thighs at 4-week intervals.
  • Anal HPV DNA was detected using L1 consensus primer-based PCR followed by type-specific probing and dot-blot hybridization (DBH).
  • HPV16, 18 and 31 DNA copy numbers were measured using quantitative real-time PCR.
  • RESULTS: There were no drug-related serious adverse events or significant changes in HIV viral load and CD4/CD8 ratio.
  • At 48 weeks, two of five participants in both the 100 and 500 microg cohorts regressed to AIN 1 and one of five participants in the 1000 microg cohort regressed to atypical squamous cells of undetermined significance (ASC-US).
  • All participants had at least one oncogenic HPV type at baseline.
  • Three of five (60%) participants who regressed to AIN 1 or ASC-US became HPV-negative using DBH and real-time PCR, compared with none of 10 participants with no clinical response (P = 0.02).
  • [MeSH-major] Anus Neoplasms / therapy. Cancer Vaccines / therapeutic use. Carcinoma in Situ / therapy. HIV Seropositivity / complications
  • [MeSH-minor] Adult. Bacterial Proteins / immunology. CD4 Lymphocyte Count. CD8-Positive T-Lymphocytes / immunology. Chaperonin 60. Chaperonins / immunology. Dose-Response Relationship, Immunologic. Female. HIV-1 / isolation & purification. Human papillomavirus 16 / immunology. Humans. Lymphocyte Count. Male. Middle Aged. Papillomaviridae / isolation & purification. Papillomavirus E7 Proteins / immunology. Papillomavirus Infections / complications. Papillomavirus Infections / therapy. Recombinant Fusion Proteins. Vaccination / methods. Viral Load. Viral Vaccines / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691066.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR 00079; United States / NCI NIH HHS / CA / U01 CA 70019; United States / NCI NIH HHS / CA / U01 CA 70047
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cancer Vaccines; 0 / Chaperonin 60; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / Viral Vaccines; 0 / heat-shock protein 65, Mycobacterium; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


7. Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M: A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS; 2010 Sep 24;24(15):2331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod.
  • OBJECTIVE: To determine whether imiquimod was more effective than placebo for the treatment of high-grade anal canal intraepithelial neoplasia (HG-ACIN).
  • METHODS: Sixty-four HIV-positive patients were randomized to self-application of imiquimod cream or matched placebo into the anal canal three times a week for 4 months.
  • Response was assessed by cytology, high-resolution anoscopy and biopsy 2 months after therapy.
  • All patients who failed to resolve were offered treatment with open-label imiquimod for a further 4 months.
  • RESULTS: Fifty-three patients completed the study, of which 28 patients were on active drug and 25 patients on placebo.
  • In the imiquimod group, four patients resolved and eight patients downgraded to low-grade squamous intraepithelial lesion (LSIL) with a median follow-up of 33 months.
  • Imiquimod was significantly associated with a positive outcome (P = 0.003).
  • Twenty-one patients entered a second open-label phase of treatment.
  • Five of these patients cleared their anal canal intraepithelial neoplasia (ACIN) and four patients downgraded to LSIL.
  • During this extended follow-up period, 61% have exhibited sustained absence of high-grade squamous intraepithelial lesion (HSIL).
  • CONCLUSION: This study demonstrates the effectiveness of imiquimod for the treatment of ACIN, and the benefit of prolonged or repeated treatments.
  • This form of therapy is likely to be especially valuable for patients with widespread multifocal ACIN who are otherwise difficult to treat, and should be considered as an adjunct to ablative therapy.
  • [MeSH-major] Aminoquinolines / administration & dosage. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. HIV Infections / drug therapy. HIV-1 / drug effects
  • [MeSH-minor] Administration, Cutaneous. Adult. Antiretroviral Therapy, Highly Active. Double-Blind Method. Homosexuality, Male. Humans. Male


8. Berkova Z, Kaufmann RH, Unger ER, Reeves WC, Adam E: The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. Am J Obstet Gynecol; 2003 Apr;188(4):932-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy.
  • OBJECTIVE: This study was undertaken to assess the effect of the time interval between referral cytology and the outcome of colposcopically directed biopsy in relation to human papillomavirus (HPV) DNA detected by polymerase chain reaction in women referred after abnormal Papanicolaou (Pap) smears.
  • STUDY DESIGN: The study enrolled 453 women who were referred for colposcopic examination after two Pap smears were reported as atypical squamous cells of undetermined significance (ASCUS) or low-grade intraepithelial lesions (LSIL) and 553 women who were referred with a single smear reported as high-grade squamous intraepithelial lesions (HSIL).
  • RESULTS: The results in both patient groups were evaluated in time intervals of 60 days or more, 61 to 120 days, and more than 120 days between referral and colposcopy.
  • Women of all race/ethnic backgrounds referred with HSIL were seen within 60 days in a significantly larger proportion than women referred with ASCUS/LSIL.
  • Women referred with ASCUS/LSIL had an increasing frequency of negative HPV findings with the prolonged time intervals.
  • In women referred with a single smear of HSIL, there was a significantly decreasing trend over time in detection of low-risk and unidentified types of HPV and an increasing trend of HPV DNA negative results.
  • CONCLUSION: The frequency of high-risk HPV DNA was similar in patients referred with ASCUS/LSIL or HSIL.
  • In both referral groups, there was a time-dependent increase of negative biopsy results and a decreased frequency of low-risk HPV or of unidentified HPV types.
  • This suggests that the initial abnormality on the Pap smear associated with other than high-risk HPV types may regress over time.
  • The presence of high-risk HPV DNA does not predict the actual histologically verifiable tissue changes but indicates a lower probability of negative biopsy results in all time intervals between referral and biopsy.
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Papanicolaou Test. Time Factors. Vaginal Smears

  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner's Manual .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12712088.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 200-92-0537
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


9. Brändlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Müller-Hermelink HK, Vollmers HP: CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep; 2004 Apr;11(4):777-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This CFR-1/PAM-1 receptor is post-transcriptionally modified and over-expressed on human epithelial tumors and carcinoma pre-cancer lesions such as H. pylori induced gastritis, intestinal metaplasia and dysplasia of the stomach, ulcerative colitis-related dysplasia and adenomas of the colon, Barrett metaplasia and dysplasia of the esophagus, squamous cell metaplasia and dysplasia of the lung and cervical intraepithelial neoplasia.
  • Furthermore, the expression of CFR-1/PAM-1 correlates with the proliferation rate and increases with the grade of malignancy.
  • Both, the unique tumor-specific expression of the CFR-1/PAM-1 receptor and the growth inhibitory effect of the PAM-1 antibody makes this combination a good diagnostic and therapeutic tool for all kinds of epithelial cancers and precursor lesions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Apoptosis. Carcinoma / drug therapy. Receptors, Cell Surface / antagonists & inhibitors. Sialoglycoproteins / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Biological Assay. Cell Line, Tumor. Humans. Immunochemistry. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Pepsin A / chemistry. Receptors, Fibroblast Growth Factor. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncol Rep. 2004 Jul;12(1):201
  • (PMID = 15010872.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / PAM-1 monoclonal antibody, human; 0 / Receptors, Cell Surface; 0 / Receptors, Fibroblast Growth Factor; 0 / Sialoglycoproteins; 0 / cysteine-rich fibroblast growth factor receptor; EC 3.4.23.1 / Pepsin A
  •  go-up   go-down


10. Zanoschi Ch, Anton C, Anton E, Costăchescu G, Teleman S, Costăchescu G, Ciupilan I, Cărăuleanu M, Cărăuleanu A, Leica V, Pânzaru C, Grigore M, Merticaru I, Huianu O, Huianu L, Chifan M: [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment]. Rev Med Chir Soc Med Nat Iasi; 2004 Jul-Sep;108(3):628-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervugid ovules in cervico-vaginal infections and cervix uteri precancerous conditions treatment].
  • This medicine was authorized by the National Drug Agency (ANM, Bucureşti) in 2001.
  • RESULTS AND DISCUSSION: Healing of the subjective symptoms in 98%, healing of the leukorrhea--as a main objective symptom--in 95%; The Bethesda system cytotest was one of the inflammatory type in the most of the cases and there wew found in 85 cases: 6 ASCUS, 41 LSIL, and 37 HSIL.
  • Cervugid may be considered as an important agent in the treatment of the precancerous affections af the cervix uteri on the following reasons: zhe cure of the infections caused by chlamydia, involved in the etiology of cervical neoplasms, the cure of the HPV infection under episome form, classified in the Bethesda system within the ASCUS, AGUS or LSIL classes.
  • In addition, it is active on chlamydia and mycoplasms, always sensitive to chloramphenicol therapy.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Chloramphenicol / therapeutic use. Hydrocortisone / analogs & derivatives. Metronidazole / therapeutic use. Nystatin / therapeutic use. Precancerous Conditions / drug therapy. Uterine Cervical Dysplasia / drug therapy. Uterine Cervicitis / drug therapy. Vaginitis / drug therapy
  • [MeSH-minor] Administration, Intravaginal. Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Antiprotozoal Agents / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Papanicolaou Test. Treatment Outcome. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginitis.
  • Hazardous Substances Data Bank. NYSTATIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. CHLORAMPHENICOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832988.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antiprotozoal Agents; 0 / Cervugid; 0 / Drug Combinations; 1400-61-9 / Nystatin; 140QMO216E / Metronidazole; 3X7931PO74 / hydrocortisone acetate; 66974FR9Q1 / Chloramphenicol; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


11. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • All the patients with these lesions have a corresponding liquid-based cytology and were proved to be HPV-positive by using hybrid capture 2 methodology with probes against high-risk oncogenic HPvs. The evaluation of GR expression was performed by using the H-score system and an H-score > 50 was considered positive.
  • RESULT: GR expression was observed in normal epithelium, LSIL, HSIL and ISCC.
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism


12. Bifulco G, Mandato VD, Piccoli R, Giampaolino P, Mignogna C, Mignogna MD, Costagliola L, Nappi C: Early invasive vulvar squamous cell carcinoma arising in a woman with vulvar pemphigus vulgaris and systemic lupus erythematosus. BMC Cancer; 2010;10:324
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early invasive vulvar squamous cell carcinoma arising in a woman with vulvar pemphigus vulgaris and systemic lupus erythematosus.
  • Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect many parts of the body and the skin with occasional bullous lesions.
  • Here, we report the first case of a woman affected with SLE presenting with early invasive squamous cell carcinoma (SCC) arising from Pemphigus Vulgaris of the vulva.
  • CASE PRESENTATION: A 27-year-old Caucasian woman was admitted to our Gynaecology Unit for bleeding vegetant lesions of the vulva.
  • Biopsy showed concomitant PV and vulvar intraepithelial neoplasia (VIN) grade 3.
  • Despite chemotherapy, no remission of disease was observed.
  • Moreover, a biopsy should be always performed if there are PV lesions because of the possibility of neoplastic disease.
  • [MeSH-major] Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / etiology. Lupus Erythematosus, Systemic / complications. Pemphigus / complications. Vulvar Diseases / complications. Vulvar Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Time Factors


13. Sharma A, Rajappa M, Saxena A, Sharma M: Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer. Mol Diagn Ther; 2007;11(3):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.
  • Cervical cancer develops from pre-neoplastic cervical intraepithelial neoplasia (CIN).
  • This study was conducted to evaluate telomerase activity as a tumor marker for the detection of cancer in patients with CIN and cervical cancer.
  • METHODS: Telomerase activity was detected using the PCR-based telomeric repeat amplification protocol (TRAP) assay in cervical tissues collected by routine punch biopsy from the uterine cervix of patients with suspected cervical cancer.
  • A total of 125 patients (including 50 patients with CIN and 75 patients with cervical cancer [including nine patients with adeno-squamous disease]) and 22 control subjects were studied.
  • RESULTS: Patients with grade I, II, and III CIN showed 17%, 33%, and 57% positivity for telomerase, respectively.
  • In the present study, telomerase positivity correlated significantly with the detection of HR HPV-16 and -18 (p < 0.001).
  • As a diagnostic test, none of the described analyses combined a sensitivity of > or =90% with a specificity of > or =90%, except in patients with advanced cancer when telomerase activity was used as a diagnostic test.
  • CONCLUSION: Our findings suggest that telomerase activation is a relatively early event in cervical carcinogenesis and correlates with the grade of cervical lesion, HR-HPV status (16 and 18 subtypes), and clinical staging.
  • Hence, these associations suggest it as a possible target for detection of cervical cancer.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / enzymology. Human papillomavirus 16 / metabolism. Human papillomavirus 18 / metabolism. Papillomavirus Infections / complications. Telomerase / metabolism. Uterine Cervical Neoplasms / enzymology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1992 Dec;73 ( Pt 12):3263-8 [1335027.001]
  • [Cites] J Clin Microbiol. 1990 Mar;28(3):495-503 [1691208.001]
  • [Cites] APMIS. 2001 Sep;109(9):607-17 [11878714.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2243-8 [9619833.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):66-70 [9495361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11549-54 [9751703.001]
  • [Cites] J Virol Methods. 1993 May;42(2-3):265-79 [8390474.001]
  • [Cites] FASEB J. 1998 Jul;12(10):801-11 [9657520.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):31-5 [12499429.001]
  • [Cites] Chin Med J (Engl). 2004 Feb;117(2):202-6 [14975203.001]
  • [Cites] Hum Pathol. 2000 Oct;31(10):1304-12 [11070123.001]
  • [Cites] Int J Gynecol Cancer. 2001 Mar-Apr;11(2):100-6 [11328407.001]
  • [Cites] Clin Obstet Gynecol. 2000 Jun;43(2):352-62 [10863633.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] Drug Resist Updat. 1999 Apr;2(2):104-115 [11504478.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):658-64 [11267977.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1932-7 [9164204.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):369-82 [10863645.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):222-6 [9264566.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):664-73 [11850794.001]
  • [Cites] In Vivo. 2001 Jul-Aug;15(4):327-32 [11695225.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):396-402 [15116318.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):154-60 [10211104.001]
  • [Cites] Clin Chem Lab Med. 2002 Oct;40(10):994-1001 [12476937.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2023-8 [9816162.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):171-5 [8995569.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):1-6 [9023822.001]
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2215-20 [11072207.001]
  • [Cites] Nat Biotechnol. 1996 May;14(5):615-9 [9630953.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):93-9 [15870530.001]
  • [Cites] Obstet Gynecol. 1998 Feb;91(2):260-2 [9469286.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):911-4 [16126869.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Apr;230(4):263-70 [15792948.001]
  • [Cites] Oncol Res. 1995;7(3-4):121-30 [8555645.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):15-21 [14751132.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1319-27 [9529024.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):394-8 [10831348.001]
  • (PMID = 17570741.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


14. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • MATERIALS AND METHODS: The study was performed in 30 patients with a mean age of 54 years and previous diagnoses from reviewed records and histopathology slides selected from a group of 65 patients with VAIN from 1980 to 1998.
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology






Advertisement